Homepage Top Section2

Opfolda will be used as an enzyme stabiliser of cipaglucosidase alfa long-term enzyme replacement therapy in LOPD (acid α glucosidase [GAA] deficiency) adult patients. The European Commission (EC)

The company has invested €350m in the new research and development (R&D) centre, representing its largest single investment in the country to date. The new high-tech facility will

Known as DERMAdoctor Comfort + Joy Psoriasis Therapeutic Moisturizing Cream with 3% salicylic acid, the product will be introduced on the QVC network. The new cream will be

This partnership will focus on exploring joint venture (JV) opportunities for advancing a Phase II ready asset and the preclinical prodrug asset of BullFrog AI. The Phase II

Currently, the company has six fill finish lines in San Diego, US, that includes a new line which provides various configurations, such as vials, cartridges, and prefilled syringes.

A first-in-class, phosphate absorption inhibitor, Xphozah will be used to control serum phosphate in adults with chronic kidney disease (CKD) on dialysis and who had an insufficient response

This therapy helps to pace up the recovery of neutrophils (a subset of white blood cells) in the body and lower risk infection. Omisirge is intended for use

Sweden-based Abliva has announced that its drug candidate NV354 has been received orphan drug designation (ODD) from the US FDA Office of Orphan Products Development to treat mitochondrial

The multi-year strategic partnership will leverage latest molecular profiling approaches guiding patient selection and participation to accelerate precision medicine approaches across five of the therapeutic programmes of Flare.